HIM
ORMP icon

Hillsdale Investment Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Hillsdale Investment Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$430K Sell
89,300
-8,000
-8% -$31.8K 0.01% 460
2026
Q1 		$331K Buy
+97,300
New +$330K 0.01% 483

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hillsdale Investment Management's ORMP Position: Q2 2026 in Review

Hillsdale Investment Management reduced its Oramed Pharmaceuticals (ORMP) stake by 8.2% in Q2 2026, selling an estimated $31.8K and leaving 89,300 shares worth $430K. The position accounts for 0.01% of the portfolio, ranked #460.

Hillsdale Investment Management first reported a position in ORMP in Q1 2026 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Hillsdale Investment Management held 89,300 shares of Oramed Pharmaceuticals worth $430K as of Q2 2026.
  • Hillsdale Investment Management sold 8,000 Oramed Pharmaceuticals shares in Q2 2026, an estimated $31.8K.
  • Oramed Pharmaceuticals made up 0.01% of Hillsdale Investment Management's portfolio in Q2 2026, its #460 holding.
  • Hillsdale Investment Management first reported a position in Oramed Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.